Sarcoma × Endocrine × 90 days × Clear all
NCT06638931 2026-04-15

ANTARES

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
28 enrolled
NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA
NCT02568267 2026-03-06

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 2 FDA
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled